Abstract
Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin® (Dibasic Calcium Phosphate Anhydrous), Pineflow® (Porous-structured Maltodextrin), Neusilin® (Magnesium Alumino metasilicate) and Aerosil® (Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.
Similar content being viewed by others
References
Amidon GL, Lennernas H, Shah VP (1995) A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420
Balakrishnan A, Rege BD, Amidon GL, Polli JE (2004) Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci 93:2064–2075
Barzegar-jalali M, Valizadeh H, Dastmalchi S (2007) Enhancing dissolution rate of carbamazepine via cogrinding with crospovidone and hydroxypropylmethylcellulose. Iran J Pharm Res 6:159–165
Cabral HM, Hadgraft J, Kellaway IW (1990) Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm 63:259–266
Clemett D, Goa KL (2000) Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59:957–980
Gupta VR, Mutalik S, Patel MM, Jani GK (2007) Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties. Acta pharm 57:173–184
Hu L, Zhang N, Yang G, Zhang J (2011) Effects of Tween-80 on the dissolution properties of Daidzein solid dispersion in vitro. Int J Chem 3:68–73
Jallo LJ, Ghoroi C, Gurumurthy L, Patel U, Davé RN (2012) Improvement of flow and bulk density of pharmaceutical powders using surface modification. Int J Pharm 423:213–225
Lu GW, Hawley M, Smith M, Geiger BM, Pfund W (2006) Characterization of a novel polymorphic form of celecoxib. J Pharm Sci 95:305–317
Morgen M, Bloom C, Beyerinck R, Bello A, Song W, Wilkinson K, Steenwyk R, Shamblin S (2012) Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm Res 29:427–440
Nagarsenker MS, Joshi MS (2005) Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev Ind Pharm 31:169–178
Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan BO, Maziasz TJ, Cook CS, Karim A (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans : effect of food and site of absorption. J Pharmacol Exp Ther 297:638–645
Punitha S, Hari BN, Karthikeyan D (2010) Enhancement of celecoxib solubility by solid dispersion using mannitol. J Pharm Pharm Sci 2:4–6
Rawat S, Jain SK (2004) Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes. Eur J Pharm Biopharm 57:263–267
Reddy MN, Rehana T, Ramakrishna S, Chowdhary KP, Diwan PV (2004) Beta-cyclodextrin complexes of celecoxib : molecular-modeling, characterization, and dissolution studies. AAPS PharmSci 6:1–9
Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB (2007) Celecoxib: Nicotinamide dissociation: using excipients to capture the cocrystal’s potential. Mol Pharm 4:386–400
Santomaso A, Lazzaro P, Canu P (2003) Powder flowability and density ratios: the impact of granules packing. Chem Eng Sci 58:2857–2874
Savjani KT, Gajjar AK, Savjani JK (2012) Drug solubility: importance and enhancement techniques. ISRN Pharm 2012:195727
Shah RB, Tawakkul MA, Khan MA (2008) Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech 9:250–258
Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Guzma CR, Gardner CR, Chen H, Moreau J (2007) Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 96:2686–2702
Vadher AH, Parikh JR, Parikh RH, Solanki AB (2009) Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. AAPS PharmSciTech 10:606–614
Vasconcelos T, Sarmento B, Costa P (2007) Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12:1068–1075
Wong SM, Kellaway IW, Murdan S (2006) Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm 317:61–68
Acknowledgments
This article does not contain any studies with human and animal subjects performed by any of the authors. And all authors (S Chakma, P Khadka, K Jo, H Kim, J Ro, K Park, S Karki, S Barua, and J Lee) declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chakma, S., Khadka, P., Jo, K. et al. Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms. Journal of Pharmaceutical Investigation 45, 449–460 (2015). https://doi.org/10.1007/s40005-015-0192-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-015-0192-1